Alignment Across Evidence, Labeling, and Clinical Use

FDA review of surgical devices often exposes misalignment among clinical evidence, intended claims, labeling, workflow, and real-world use.

Each element may appear reasonable in isolation. The full program may not.

The clinical study may support one use case while the proposed labeling describes another. The trial setting may not reflect community practice. The regulatory pathway may assume clinical consensus that does not exist. Product-risk controls may not account for how users actually interact with the device.

Early signals often appear as FDA questions that do not fit the team’s precedent analysis, concerns from clinical staff, or disagreement between regulatory and commercial teams.

Once these issues are embedded in a submission, resolution usually requires more time and evidence. Earlier review can identify the mismatch while study design, claims, labeling, and risk controls can still be changed.

Independent review is most useful at these decision points: before the evidence plan is fixed, before an FDA meeting, or when the team cannot reconcile the agency’s feedback with its existing strategy.